Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi, Debiopharm Deals Buy ImmunoGen Extra Time

Executive Summary

ImmunoGen has turned around two cash-generation deals in a week as it seeks to extend its funding and narrow its focus. It has sold one asset to Debiopharm and foregone future royalties on five products licensed to Sanofi in exchange for an upfront lump sum.

You may also be interested in...



Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

ImmunoGen sucks up the cost of novelty value

The clinical disappointment for Hoffman-La Roche's Kadcyla (trastuzumab emtansine) in December 2014 has forced Boston-based ImmunoGen, which licenses the toxin and linker of Kadcyla to Roche, into an expensive $200m deal on its near-term royalties on Kadcyla for cash to maintain R&D spending. Under the deal, ImmunoGen will receive the cash in early April 2015 from TPG Special Situations Partners (TSSP), a specialist finance house, and then will see nothing of the Kadcyla royalty stream until TSSP has received at least $235m (if the royalties flow in) or $260m (if it's a trickle).

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC098831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel